L ong QT intervals corrected for rate (QTc) >480 to 500 milliseconds predispose to the polymorphic ventricular tachycardia torsades de pointes (TdP). 1 Because QTc is shorter and TdP is less frequent in men than in women and because testosterone shortens ventricular repolarization, we examined the effect of hypogonadism and androgen deprivation therapy (ADT) on QTc and TdP risk. 2 We prospectively evaluated testosterone and related plasma levels in each man seen with TdP (n=7) over 19 months at a single university hospital (Hôpital Pitié-Salpétrière, Paris, France, Commission nationale de l'informatique et des libertés No. 1491960v0, patients' informed consent obtained). We then analyzed the European pharmacovigilance database (up to June 2017, URL: https://clinicaltrials.gov, Unique identifier: NCT03193138) searching for QTc/TdP adverse drug reactions (Medical Dictionary for Regulatory Activities terms: long-QT syndrome [LQT], ECG QT-prolonged, and TdP) associated with ADT, and we performed a cross-sectional analysis of the association between the International Classification of Diseases revisions 9 and 10 codes for LQT/TdP and hypogonadism in 1.1 million men in a US electronic health record cohort (up to November 2017, Vanderbilt University Medical Center, Institutional Review Board approval no. 171796). 3 Hypogonadism was diagnosed in 7 of 7 cases of TdP (Table) . After correction of low testosterone levels, QTc shortened and there was no TdP recurrence. Three patients had spontaneous reversal of hypogonadism after resolution of a severe critical illness; 3 patients needed testosterone supplementation for chronic hypogonadism; and 1 patient died. LQT genetic screening was negative in 6 of the 6 tested patients.
L ong QT intervals corrected for rate (QTc) >480 to 500 milliseconds predispose to the polymorphic ventricular tachycardia torsades de pointes (TdP). 1 Because QTc is shorter and TdP is less frequent in men than in women and because testosterone shortens ventricular repolarization, we examined the effect of hypogonadism and androgen deprivation therapy (ADT) on QTc and TdP risk. 2 We prospectively evaluated testosterone and related plasma levels in each man seen with TdP (n=7) over 19 months at a single university hospital (Hôpital Pitié-Salpétrière, Paris, France, Commission nationale de l'informatique et des libertés No. 1491960v0, patients' informed consent obtained). We then analyzed the European pharmacovigilance database (up to June 2017, URL: https://clinicaltrials.gov, Unique identifier: NCT03193138) searching for QTc/TdP adverse drug reactions (Medical Dictionary for Regulatory Activities terms: long-QT syndrome [LQT] , ECG QT-prolonged, and TdP) associated with ADT, and we performed a cross-sectional analysis of the association between the International Classification of Diseases revisions 9 and 10 codes for LQT/TdP and hypogonadism in 1.1 million men in a US electronic health record cohort (up to November 2017, Vanderbilt University Medical Center, Institutional Review Board approval no. 171796). 3 Hypogonadism was diagnosed in 7 of 7 cases of TdP (Table) . After correction of low testosterone levels, QTc shortened and there was no TdP recurrence. Three patients had spontaneous reversal of hypogonadism after resolution of a severe critical illness; 3 patients needed testosterone supplementation for chronic hypogonadism; and 1 patient died. LQT genetic screening was negative in 6 of the 6 tested patients.
The European pharmacovigilance database (http://www.adrreports.eu/fr/ search.html) analysis identified 43 of 34 221 individual case safety reports of men with drug-induced (di) LQT (diLQT) and 15 of 34 221 with diTdP suspected to be attributable to ADT versus none (0 of 10 847) reported during testosterone replacement therapy. ADT included the following pharmacological classes of drugs: gonadotrophin-releasing hormone receptor agonists (leuprolide, buserelin, goserelin, triptorelin), gonadotrophin-releasing hormone receptor antagonist (degarelix), cytochrome-17 inhibitor (abiraterone), nonsteroidal androgen receptor antagonists (bicalutamide, flutamide, nilutamide, enzalutamide), and 5α-reductase inhibitors (finasteride, dutasteride). Disproportionality analysis showed higher reporting odds ratios (ORs) 4 Taken together, these data provide consistent support for an association between hypogonadism in men and LQT/TdP. The association appears to be causal because correction of hypogonadism by testosterone replacement therapy can treat or prevent TdP and ADT can lead to LQT/TdP. These results provide strong justifi-cation for a clinical recommendation to investigate the possibility of hypogonadism when TdP occurs in men. Hypogonadism should be added to the list of risk factors for TdP, and an increased awareness should prompt correction of other TdP risk factors in men receiving ADT.
Our findings support the hypothesis that hypogonadism is a correctable and readily identifiable risk factor for TdP in men. There should be a high index of suspicion when symptoms such as erectile dysfunction, testicular hypotrophy, and hot flashes are present, particularly when the prevalence of hypogonadism is expected to be high such as in elderly men. It has been shown that hypothalamic-pituitary-gonadal axis physiology is dramatically altered during critical illnesses and after major surgery or brain injury and can lead to tran- ICD upgrading while changing pacemaker
Bio-T indicates bioavailable testosterone; ECD, Erdheim-Chester disease; EF, ejection fraction (left ventricle); FSH, follicle-stimulating hormone; ICD, implantable cardioverter-defibrillator; LH, luteinizing hormone; and TdP, torsades de pointes.
*Hypogonadic men with high FSH and LH were classified as having peripheral hypogonadism, whereas those with inappropriately normal or low FSH and LH were considered to have central hypogonadism. Normal values for adult men in our laboratory are as follows: FSH, 1.5 to 12.4 IU/L; LH, 1.7 to 8.6 IU/L; and Bio-T, 1 to 3.2 ng/mL. A progressive decrease in Bio-T normal values is expected with increasing age (up to 40% at 90 years of age).
†According to the CredibleMeds website (https://crediblemeds.org/). Table) , awaiting a spontaneous normalization of pituitary function. Late-onset hypogonadism has recently been defined as a syndrome in middle-aged and elderly men reporting sexual symptoms associated with higher cardiovascular mortality in the presence of low testosterone levels (eg, patients 2 and 3). 5 In our case series, TdP did not recur after testosterone supplementation. The basic mechanisms are not completely defined, but preclinical studies show that testosterone increases the repolarizing potassium currents I Kr and I Ks and decreases the depolarizing L-type calcium current. 2 ADT is a cornerstone of the treatment of prostate cancer. Among ADTs, the website crediblemeds.org currently lists only degarelix and leuprolide as possible risks for TdP, so further guideline updates may be needed for newer drugs such as abiraterone.
A limitation of the analyses of the pharmacovigilance database and the electronic health record is that the data come from uncontrolled sources. Nevertheless, the case series and the population analyses provide orthogonal validation for the causal, and treatable, relationship we postulate between male hypogonadism and TdP risk.
